• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Dysport competition: Derms easing into use of abobotulinumtoxinA for treatment of glabellar lines


Dysport is being touted as the first serious competitor to Botox.

Dysport is being touted as the first serious potential competitor to Botox (onabotulinumtoxinA, Allergan), the long-standing, unique therapy used to reduce the appearance of facial wrinkles by restricting muscle action in the face.

On Call wondered if dermatologists were chomping at the bit to try this new anti-wrinkle therapy, or if there was little need for the new product.

In a very random sampling of physicians from around the country, On Call did find interest in Dysport. Doctors think it offers potential, but a lot of dermatologists seem to be taking a measured approach to trying it, rather than jumping in with both feet.

Dysport in practice

Melinda F. Greenfield, D.O., has a large solo practice in Albany, Ga. She draws patients from a population of about 300,000 and was ready to move forward.

"I have it sitting in my freezer, but haven't used it on a patient yet," Dr. Greenfield says.

"The problem is, the rep who sold it to me said he would come back and talk me through the dilution technique and all of it. I have never heard back from him," she says.

Dr. Greenfield, associate clinical professor, Philadelphia College of Osteopathic Medicine, Georgia campus, says she knows she could handle this on her own, but the pressure hasn't been there.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.